BC Extra | Jan 24, 2020
Clinical News

Ipsen’s $1B bet on Clementia fizzles with FOP trial stop

Ipsen has paused the clinical program for palovarotene in FOP, the asset behind its $1 billion acquisition of Clementia. The move puts the CVR that came with the deal at serious risk and could give...
BC Extra | Jan 17, 2020
Company News

Management tracks: Sun departs as Hengrui chair; plus Blackstone, Ipsen, bluebird, BioNTech, Catalent, Foundation, Twist, Lantheus, Abcam and more

Jiangsu Hengrui Medicine Co Ltd. (Shanghai:600276) said Piaoyang Sun will step down as chairman. Sun, who has led the company for 30 years, will continue to serve on the board’s strategy committee and is succeeded...
BC Extra | Dec 18, 2019
Company News

Ipsen’s Meek to helm Ferring’s gene therapy unit

David Meek will step down as CEO of Ipsen at year end to become president and CEO of Ferring’s newly formed gene therapy subsidiary, effective Jan. 14. Ferring Pharmaceuticals A/S and Blackstone Life Sciences launched...
BC Extra | Dec 6, 2019
Company News

FDA hold muddies Ipsen’s timeline for palovarotene in rare bone disease

A partial clinical hold on four studies of palovarotene that shaved $1.1 billion from Ipsen’s market cap on Friday could slow the biopharma’s timeline for a planned NDA to treat rare bone disease fibrodysplasia ossificans...
BC Extra | Dec 4, 2019
Company News

Management tracks: Mittal to succeed Biocon’s Chandavarkar; plus Intercept, Nektar, Agios, Accelerate, ABPI and more

CFO Siddharth Mittal will succeed Arun Chandavarkar as CEO and joint managing director of Biocon Ltd. (NSE:BIOCON; BSE:532523). Chandavarkar, who retired last month, had been with the Indian biopharma since 1990. Mittal joined in 2013...
BC Extra | Nov 16, 2019
Company News

Management tracks: Lonza CEO to step down; plus Arrowhead, Insmed, Inozyme, Yukin, Pfenex, EyePoint, Verseau, Abingworth, CBC, Flagship, Diverse, Theragnostics,

Lonza Group Ltd. (SIX:LONN) CEO Marc Funk will leave the company in January for personal reasons. Chairman Albert Baehny will take on the CEO responsibilities on an interim basis. Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) said COO...
BC Extra | Nov 9, 2019
Company News

Management tracks: Teva, Ipsen, ADC, Assembly, Kaleido, Biodesix, CorMedix, Ideaya, Partner, Neurana, Odylia and T1D Exchange

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) hired Eli Kalif as EVP and CFO, effective Dec. 22. He succeeds Michael McClellan, who stepped down Friday for personal reasons. Kalif was SVP, finance at Flex Ltd....
BC Extra | Oct 16, 2019
Company News

Ipsen doubles down on rare musculoskeletal disease via Blueprint deal

Ipsen redoubled its commitment to developing treatments for fibrodysplasia ossificans progressiva by obtaining rights to an ALK2 inhibitor from Blueprint. The deal gives Ipsen Group (Euronext:IPN; Pink:IPSEY) exclusive, worldwide rights to BLU-782 from Blueprint Medicines...
BioCentury | Jul 19, 2019
Finance

Earnings on deck

Earnings on deck At least 10 profitable biotechs and pharmas are slated to report earnings this week. (A) During market hours in Europe, premarket on U.S. exchanges; (B) Six-month EPS Company Date Pre/post mkt 2Q19...
BC Extra | Jul 17, 2019
Financial News

Bayer-backed Pyxis debuts with $22M to pursue new immuno-oncology targets

Pyxis’ tumor microenvironment-based technology to identify immuno-oncology targets developed by cancer researcher Thomas Gajewski prompted Leap by Bayer to lead the start-up’s $22 million series A round. Agent Capital, Ipsen Group (Euronext:IPN; Pink:IPSEY), Longwood and...
Items per page:
1 - 10 of 916
BC Extra | Jan 24, 2020
Clinical News

Ipsen’s $1B bet on Clementia fizzles with FOP trial stop

Ipsen has paused the clinical program for palovarotene in FOP, the asset behind its $1 billion acquisition of Clementia. The move puts the CVR that came with the deal at serious risk and could give...
BC Extra | Jan 17, 2020
Company News

Management tracks: Sun departs as Hengrui chair; plus Blackstone, Ipsen, bluebird, BioNTech, Catalent, Foundation, Twist, Lantheus, Abcam and more

Jiangsu Hengrui Medicine Co Ltd. (Shanghai:600276) said Piaoyang Sun will step down as chairman. Sun, who has led the company for 30 years, will continue to serve on the board’s strategy committee and is succeeded...
BC Extra | Dec 18, 2019
Company News

Ipsen’s Meek to helm Ferring’s gene therapy unit

David Meek will step down as CEO of Ipsen at year end to become president and CEO of Ferring’s newly formed gene therapy subsidiary, effective Jan. 14. Ferring Pharmaceuticals A/S and Blackstone Life Sciences launched...
BC Extra | Dec 6, 2019
Company News

FDA hold muddies Ipsen’s timeline for palovarotene in rare bone disease

A partial clinical hold on four studies of palovarotene that shaved $1.1 billion from Ipsen’s market cap on Friday could slow the biopharma’s timeline for a planned NDA to treat rare bone disease fibrodysplasia ossificans...
BC Extra | Dec 4, 2019
Company News

Management tracks: Mittal to succeed Biocon’s Chandavarkar; plus Intercept, Nektar, Agios, Accelerate, ABPI and more

CFO Siddharth Mittal will succeed Arun Chandavarkar as CEO and joint managing director of Biocon Ltd. (NSE:BIOCON; BSE:532523). Chandavarkar, who retired last month, had been with the Indian biopharma since 1990. Mittal joined in 2013...
BC Extra | Nov 16, 2019
Company News

Management tracks: Lonza CEO to step down; plus Arrowhead, Insmed, Inozyme, Yukin, Pfenex, EyePoint, Verseau, Abingworth, CBC, Flagship, Diverse, Theragnostics,

Lonza Group Ltd. (SIX:LONN) CEO Marc Funk will leave the company in January for personal reasons. Chairman Albert Baehny will take on the CEO responsibilities on an interim basis. Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) said COO...
BC Extra | Nov 9, 2019
Company News

Management tracks: Teva, Ipsen, ADC, Assembly, Kaleido, Biodesix, CorMedix, Ideaya, Partner, Neurana, Odylia and T1D Exchange

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) hired Eli Kalif as EVP and CFO, effective Dec. 22. He succeeds Michael McClellan, who stepped down Friday for personal reasons. Kalif was SVP, finance at Flex Ltd....
BC Extra | Oct 16, 2019
Company News

Ipsen doubles down on rare musculoskeletal disease via Blueprint deal

Ipsen redoubled its commitment to developing treatments for fibrodysplasia ossificans progressiva by obtaining rights to an ALK2 inhibitor from Blueprint. The deal gives Ipsen Group (Euronext:IPN; Pink:IPSEY) exclusive, worldwide rights to BLU-782 from Blueprint Medicines...
BioCentury | Jul 19, 2019
Finance

Earnings on deck

Earnings on deck At least 10 profitable biotechs and pharmas are slated to report earnings this week. (A) During market hours in Europe, premarket on U.S. exchanges; (B) Six-month EPS Company Date Pre/post mkt 2Q19...
BC Extra | Jul 17, 2019
Financial News

Bayer-backed Pyxis debuts with $22M to pursue new immuno-oncology targets

Pyxis’ tumor microenvironment-based technology to identify immuno-oncology targets developed by cancer researcher Thomas Gajewski prompted Leap by Bayer to lead the start-up’s $22 million series A round. Agent Capital, Ipsen Group (Euronext:IPN; Pink:IPSEY), Longwood and...
Items per page:
1 - 10 of 916